| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6d4c177e8a1464ce532b4644976972f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2400-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96455 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21077 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2015-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7df1ccbc15d7e29358aceeba3961b1d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_558ca2ba2836fcb0e57421160333be8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_245d11a81371c61347119b469e5e8da0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce0a7114e9e147ebe97668bdb6a0733f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0b5016716f960d77215393919c6a134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeb9ee9c0da4b9320658fcde56e082a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e130f10c9453cd5a0af36ee67a9f32f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9498c65e4818d03002b49afd6cd139d6 |
| publicationDate |
2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10151754-B2 |
| titleOfInvention |
Cell surface prostate cancer antigen for diagnosis |
| abstract |
The present invention provides compositions and methods of detecting prostate cancer in the body fluids or tissues of patients. Prostate cancer is detected by measuring the level of glypican-1 in a body fluid sample. In one embodiment prostate cancer is detected by contacting a body fluid sample with an anti-glypican-1 antibody, such as MIL-38. The invention includes kits for detection of prostate cancer in a body fluid sample, comprising an anti-glypican-1 antibody and glypican-1 standards. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11198738-B2 |
| priorityDate |
2014-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |